Depatuxizumab Mafodotin

Depatuxizumab Mafodotin Uses, Dosage, Side Effects, Food Interaction and all others data.

Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.

Selectively targets cancer cells expressing mutant epidermal growth factor receptor (EGFR) vIII or over expressing wild type EGFR . Depatuxizumab Mafodotin acts on these cells to inhibit microtuble polymerization thus disrupting mitosis and vesicular trafficking

Table Of contents

• Depatuxizumab Mafodotin
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Depatuxizumab Mafodotin
Generic	Depatuxizumab mafodotin
Depatuxizumab mafodotin Other Names	Denintuzumab mafodotin, Depatuxizumab mafodotin
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

No approved indication.

How Depatuxizumab Mafodotin works

Depatuxizumab is a chimeric monoclonal antibody for EGFR which is linked to monomethyl aurastatin F via a maleimidocaproyl linker (mafodotin) . Once delivered to the cancer cell, the mafodotin component is able to bind to tubulin and inhibit the exchange of GDP for GTP necessary for the polymerization of tubulin subunits to form microtubules. The inhibition of microtubule polymerization disrupts mitosis and interferes with vesicle trafficking in the cancer cell .

Innovators Monograph

You find simplified version here Depatuxizumab Mafodotin